These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 15383641

  • 1. Ximelagatran: an oral direct thrombin inhibitor.
    Dager WE, Vondracek TG, McIntosh BA, Nutescu EA.
    Ann Pharmacother; 2004 Nov; 38(11):1881-97. PubMed ID: 15383641
    [Abstract] [Full Text] [Related]

  • 2. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C, Mouret P.
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [Abstract] [Full Text] [Related]

  • 3. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J, Ingrid J, Tivadar F.
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [Abstract] [Full Text] [Related]

  • 4. Ximelagatran: a new oral anticoagulant.
    Hrebickova L, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Nov; 5(6):397-408. PubMed ID: 14633322
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

  • 7. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R, Tran M, Gore JM, Spencer FA.
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S, THRIVE III Investigators.
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [Abstract] [Full Text] [Related]

  • 11. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC, Perry CM, Faulds D.
    Drugs; 2004 Sep; 64(6):649-78. PubMed ID: 15018597
    [Abstract] [Full Text] [Related]

  • 12. Ximelagatran: a new oral anticoagulant.
    Francis CW.
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):139-52. PubMed ID: 15171963
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S.
    Pathophysiol Haemost Thromb; 2005 Mar; 34 Suppl 1():18-24. PubMed ID: 15812200
    [Abstract] [Full Text] [Related]

  • 16. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC.
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV, Bounameaux H.
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [Abstract] [Full Text] [Related]

  • 19. Ximelagatran (AstraZeneca).
    Hopfner R.
    Curr Opin Investig Drugs; 2002 Feb; 3(2):246-51. PubMed ID: 12020054
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.